Role of fixed coefficients and exponents in the prediction of human drug clearance: How accurate are the predictions from one or two species?

Journal of Pharmaceutical Sciences

Volumn 98, Issue 7, 2009, Pages 2472-2493

  Mahmood, Iftekhar ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Allometric scaling; Biliary excretion; Bioavailability; Clearance

Indexed keywords

1,2,3,6 TETRAHYDRO 4 PHENYL 1 [(3 PHENYL 3 CYCLOHEXEN 1 YL)METHYL]PYRIDINE; 4 ALLYL 1,8 DIETHYL 2,3,4,9 TETRAHYDRO 1H CARBAZOLE 1 ACETIC ACID; ACTISOMIDE; AMLODIPINE; BOSENTAN; CANDOXATRIL; CITALOPRAM; DOFETILIDE; GABAPENTIN; IFETROBAN; IMIRESTAT; IRINOTECAN; LAMIFIBAN; LINEZOLID; MELOXICAM; MEROPENEM; METOPROLOL; MINAPRINE; MORPHINE; MOXIFLOXACIN; N [1 TERT BUTYL 2 OXO 2 [4 (2 THIAZOLYLMETHYL) 1 PIPERAZINYL]ETHYL] 3 CYCLOPENTYL 2 (N FORMYL N HYDROXYAMINOMETHYL)PROPIONAMIDE; NICARDIPINE; NISOLDIPINE; PELRINONE; PHENAZONE; REMIKIREN; RITIPENEM; SEMAXANIB; SILDENAFIL; SINITRODIL; TACROLIMUS; TAMSULOSIN; TOLCAPONE; TROGLITAZONE; TROVAFLOXACIN; UNINDEXED DRUG;

ACCURACY; ALLOMETRY; ARTICLE; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; HUMAN; MONKEY; MOUSE; NONHUMAN; RAT; TECHNIQUE;

EID: 67650151791     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21597     Document Type: Article

References (122)

1. Mahmood I, Green MD, Fisher JE. 2003. Selection of the first-time dose in humans: Comparison of different approaches based on interspecies scaling of clearance. J Clin Pharmacol 43:692-697. (Pubitemid 36759146)
2. Mahmood I. 2005. First-in-human dose selection. In: Interspecies pharmacokinetic scaling: Principles and application of allometric scaling. Rockville, MD: Pine House Publishers. pp 259-287.
3. Boxenbaum H. 1982. Comparative pharmacokinetics of benzodiazepines in dog and man. J Pharmacokinet Biopharm 10:411-426. (Pubitemid 13217281)
4. Caldwell GW, Masucci JA, Yan Z, Hageman W. 2004. Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted from in-vivo rat data? Eur J Drug Metab Pharmacokinet 29:133-143.
5. Bachmann K, Pardoe D, White D. 1996. Scaling basic toxicokinetic parameters from rat to man. Environ Health Perspect 104:400-407. (Pubitemid 26160825)
6. Ward KW, Smith BR. 2004. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 32:603-611. (Pubitemid 38668152)
7. Tang H, Hussain A, Leal M, Mayersohn M, Fluhler E. 2007. Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 35:1886-1893. (Pubitemid 47481583)
8. Mahmood I. 2002. Interspecies scaling: Predicting oral clearance in humans. Am J Ther 9:35-42.
9. Sinha VK, De Buck SS, Fenu LA, Smit JW, Nijsen M, Gilissen RA, Van Peer A, Lavrijsen K, Mackie CE. 2008. Predicting oral clearance in humans: How close can we get with allometry? Clin Pharmacokinet 47:35-45.
10. Mahmood I. 2005. Interspecies scaling of clearance. In: Interspecies pharmacokinetic scaling: Principles and application of allometric scaling. Rockville, MD: Pine House Publishers. pp 39-85.
11. Mahmood I, Balian JD. 1996. Interspecies scaling: Predicting clearance of drugs in humans: Three different approaches. Xenobiotica 26:887-895. (Pubitemid 26343083)
12. Mahmood I. 2004. Interspecies scaling of protein drugs: Prediction of clearance from animals to humans. J Pharm Sci 93:177-185. (Pubitemid 38081825)
13. Mahmood I. 2005. Interspecies scaling of drugs cleared by the kidneys and the bile. In: Interspecies pharmacokinetic scaling: Principles and application of allometric scaling. Rockville, MD: Pine House Publishers. pp 105-143.
14. Mahmood I. 2000. Can absolute oral bioavailability in humans be predicted from animals? A comparison of allometry and different indirect methods Drug Metab Drug Interact 143-155.
15. Lin JH. 1998. Application and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 26:1202-1212. (Pubitemid 29028641)
16. Tang H, Mayersohn M. 2005. A mathematical description of the functionality of correction factors used in allometry for predicting human drug clearance. Drug Metab Dispos 33:1294-1296. (Pubitemid 41196971)
17. Tang H, Mayersohn M. 2005. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 33:1297-1303. (Pubitemid 41196972)
18. Mahmood I. 2006. Prediction of human drug clearance from animal data: Application of the rule of exponents and 'fu Corrected Intercept Method' (FCIM). J Pharm Sci 95:1810-1821. (Pubitemid 44229587)
19. Mahmood I. 2005. Issues related to the prediction of human clearance. In: Interspecies pharmacokinetic scaling: Principles and application of allometric scaling. Rockville, MD: Pine House Publishers. pp 91-104.
20. Obach R, Baxter J, Liston T, Silber M, Jones B, MacIntyre F, Rance D, Wastall P. 1997. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58. (Pubitemid 27438945)
21. Rane A, Hogstedt S, Lindberg B, Regardh CG, Jorulf H. 1984. Comparison of different clearance estimates for metoprolol in the rhesus monkey. J Pharmacol Exp Ther 228:774-778. (Pubitemid 14156687)
22. Belpaire FM, Smet FD, Vynckier LJ, Vermeulen AM, Rosseel MT, Bogaert MG, Moachon-Chauvelot L. 1990. Effect of aging on the pharmacokinetics of metoprolol and propranolol in the rat. J Pharmacol Exp Ther 254:116-122. (Pubitemid 20262029)
23. Murthy SS,NelsonWL, ShenDD, Power JM, Cahill CM, McClean AJ. 1991. Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereochemical aspects. Drug Metab Dispos 19:1093-1100.
24. Siefert HM, Domdey-Bette A, Henninger K, Hucke F, Kohlsdorfer C, Stass HH. 1999. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin:A comparison in humans and other mammalian species. J Antimicrob Chem 43:69-76. (Pubitemid 29231796)
25. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, Sugiyama Y. 1996. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 277:1630-1641. (Pubitemid 27167181)
26. Loi CM, Young M, Randinitis E, Vassos A, Koup JR. 1999. Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 37:91-104.
27. Cook CS, Rozek LF, Stolzenbach J, Anderson S, Schoenhard GL, Karim A. 1993. Pharmacokinetics of a novel antiarrhythmic drug, actisomide. Pharm Res 10:427-433. (Pubitemid 23080609)
28. Higuchi S, Shiobara Y. 1980. Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. Xenobiotica 10: 447-454. (Pubitemid 10049541)
29. Miline RW, Nation RL, Somogyi A. 1996. The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab Rev 28:345-472. (Pubitemid 26300413)
30. Tang R, Girard D, Gootz TD, Foulds G, Liston TE. 1996. Pharmacokinetics of trovafloxacin (CP-99, 219), a new quinolone, in rats, dogs, and monkeys. Antimicrob Agents Chemother 40:561-566. (Pubitemid 26071522)
31. Vincent J, Dogolo L, Baris BA, Willavize SA, Tang R. 1998. Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trova- floxacin and alatrofloxacin in humans. Eur J Clin Microbiol Infect Dis 17:427-430. (Pubitemid 28427366)
32. Giachetti C, Bertolino M, Canali S, Lombardini E, Monzani MV, Sala A, Zanolo G. 1998. Pharmacokinetic study in dogs and monkeys after single intravenous and oral administrations of [14C]- ITF-296. Eur J Drug Metab Pharmacokinet 23: 239-250. (Pubitemid 28401114)
33. Monzani MV, Coltro G, Jiritano L, Sala A. 1995. Pharmacokinetic profile of ITF 296 in rats and dogs. J Cardiovasc Pharmacol S67-S71. (Pubitemid 26069771)
34. Sardina M, Love R, Mizrahi J, Monzani V, Bianchini C. 1995. Safety and pharmacologic activity of a new nitrate ester, ITF 296, after intravenous administration in healthy volunteers. J Cardiovasc Pharmacol 269:S72-S79. (Pubitemid 26069772)
35. Monzani MV, Coltro G, Sala A, Sardina M. 1999. Pharmacokinetics of ITF 296 (Sinitrodil) a novel organic nitrate, in healthy volunteers. Eur J Pharm Sci 7:179-184. (Pubitemid 29015733)
36. Kaye B, Brearley CJ, Cussans NJ,HerronM,Humphrey MJ, Mollat AR. 1997. Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog andman following administration of the prodrug candoxatril. Xenobiotica 27:1091-1102. (Pubitemid 27450599)
37. Smith DA, Rasmussen HS, Stopher DA, Walker DK. 1992. Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica 22:709-719.
38. Walker OK, Ackland MJ, James GC, Muirhead GJ, Rance OJ, Wastall P, Wright PA. 1999. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 29: 297-310. (Pubitemid 29140098)
39. Slatter JG, Adams LA, Bush EC, Chiba K, Daley- Yates PT, Feenstra KL, Koike S, Ozawa N, Peng GW, Sams JP, Schuette MR, Yamazaki S. 2002. Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 32:907-924. (Pubitemid 35155524)
40. Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH. 2003. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 51:1239-1246. (Pubitemid 36622080)
41. Stopher DA, Beresford AP, Macrae PV, Humphrey MJ. 1988. The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol 12:S55-S59. (Pubitemid 19014188)
42. Takada K, Usuda H, Ohhashi M, Yoshikawa H, Muranishi S, Tanaka H. 1991. Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administration to rats. J Pharmacobiodyn 14:34-42.
43. Venkataramanan R, Cadoff JE, Warty V, Iwasaki K, Nagase K, Krajack A, Imventarza O, Todo S, Fung J, Starzl TE. 1990. Pharmacokinetics of FK- 506: Preclinical and clinical studies. Transplant Proc 22:52-56. (Pubitemid 20112753)
44. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, Mcmichael J, Lever J, Burckhart G, Starzl T. 1995. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokin 29:404-430.
45. Matsushima H, Kamimura H, Soeishi Y, Watanabe T, Higuchi S, Tsunoo M. 1998. Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans. Drug Metab Dispos 26:240-245. (Pubitemid 28182400)
46. van Hoogdalem EJ, Soeishi Y, Matsushima H, Higuchi S. 1997. Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: Comparison with data from interspecies scaling. J Pharm Sci 86:1156-1161. (Pubitemid 27430922)
47. Busch U, Schmid I, Heinzel G, Schmaus H, Baierl I, Huber C, Roth W. 1998. Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab Disp 26:576-584. (Pubitemid 28498364)
48. Schmid I, Busch U, Heinzel G, Bozler G, Kaschke S, Kummer M. 1995. Meloxicam: Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Disp 23:1206-1213.
49. Dockens RC, Santone KS, Mitroka JG, Morrison RA, Jemal M, Greene DS, Barbhaiya RH. 2000. Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans. Drug Metab Dispos 28: 973-980. (Pubitemid 30612618)
50. Ahr HJ, Krause HP, Siefert HM, Suwelack D, Weber H. 1988. Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine. Arzneimittelforschung 38:1093-1098.
51. Kirsten R, Nelson K, Kirsten D, Heintz B. 1998. Clinical pharmacokinetics of vasodilators. Part I. Clin Pharmacokinet 34:457-482.
52. Coassolo P, Fischli W, Clozel JP, Chou RC. 1996. Pharmacokinetics of remikiren, a potent orally active inhibitor of human rennin, in rat, dog, and primates. Xenobiotica 26:333-345. (Pubitemid 26128234)
53. Kleinbloesem CH, Weber C, Fahrner E, Dellenbach M, Welker H, Schroter V, Belz GG. 1993. Hemodynamics, biochemical effects and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. Clin Pharmacol Ther 53:585-592. (Pubitemid 23161207)
54. Radulovic LL, Türck D, von Hodenberg A, Vollmer KO, McNally WP, DeHart PD, Hanson BJ, Bockbrader HN, Chang T. 1995. Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys. Drug Metab Dispos 23:441-448.
55. Bialer M. 1993. Comparative pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet 24:441-452. (Pubitemid 23160614)
56. Harrison MP, Moss SR, Featherstone A, Fowkes AG, Sanders AM, Case DE. 1989. The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother 24:265-277.
57. Ubeaud G, Schmitt C, Jaeck D, Lave T, Coassolo P. 1995. Bosentan, a new endothelin receptor antagonist: Prediction of the systemic plasma clearance in man from combined in vivo and in vitro data. Xenobiotica 25:1381-1390. (Pubitemid 26025861)
58. Scatina JA, Hicks DR, Kraml M, Cayen MN. 1990. Metabolic disposition and pharmacokinetics of pelrinone, a new cardiotonic drug, in laboratory animals and man. Eur J Drug Metab Pharmacokinet 15:37-48. (Pubitemid 20191275)
59. Lave T, Dupin S, Schmitt M, Kapps M, Meyer J, Morgenroth B, Chou RC, Jaeck D, Coassolo P. 1996. Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica 26:839-851.
60. Davi H, Bonnet JM, Berger Y. 1992. Disposition of minaprine in animals and in human extensive and limited debrisoquine hydroxylators. Xenobiotica 22:171-184.
61. Bonati M, Latini R, Tognoni G. 1984-1985. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse. Drug Metab Rev 15:1355-1383. (Pubitemid 15028349)
62. Boothe DM, Cullen JM, Calvin JA, Jenkins WL, Brown SA, Green RA, Corrier DE. 1994. Antipyrine and caffeine dispositions in clinically normal dogs and dogs with progressive liver disease. Am J Vet Res 55:254-261.
63. Inaba M, Ohnishi Y, Ishii H, Tanioka Y, Yoshida Y, Sudoh K, Hakusui H, Mizuno N, Ito K, Sugiyama Y. 1998. Pharmacokinetics of CPT-11 in rhesus monkeys. Cancer Chemother Pharmacol 41:103-108.
64. Kaneda N, Yokokura T. 1990. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50:1721-1725. (Pubitemid 20098810)
65. Kaneda N, Nagata H, Furuta T, Yokokura T. 1990. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50:1715-1720. (Pubitemid 20098809)
66. Rothenberg ML, Kuhn JG, Burris HA 3rd, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI. 1993. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204.
67. Overo FK. 1982. Kinetics of citalopram in test animals; drug exposure in safety studies. Prog Neuro-Psychopharmacol BioI Psychiat 6:297-309. (Pubitemid 13255332)
68. Eriksson UG, Renberg L, Bredberg U, Teger- Nilsson AC, Regardh CG. 1998. Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug. Biopharm Drug Dispos 19:55-64. (Pubitemid 28064491)
69. Hauptmann J. 2002. Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. A. review of small-molecule thrombin inhibitors. Eur J Clin Pharmacol 57:751-758. (Pubitemid 34143330)
70. Kita Y, Fugono T, Imada A. 1986. Comparative pharmacokinetics of carumonam and aztreonam in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother 29:127-134. (Pubitemid 16155235)
71. Berube D, Vallee F, Panneton A-C, Bergeron MG, Lebel M. 1988. Pharmacokinetics of carumonam after single and multiple 1- and 2-g dosage regimens. Antimicrob Agents Chemother 32:354-357. (Pubitemid 18063563)
72. Balani SK, Zhu T, Yang TJ, Liu Z, He B, Lee FW. 2002. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Drug Metab Disp 30: 1059-1062.
73. Bachmann K. 1989. Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species. J Appl Toxicol 9:331-338. (Pubitemid 19230512)
74. Lave T, Saner A, Coassolo P, Brandt R, Schmitt- Hoffmann AH, Chou RC. 1996. Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. J Pharm Pharmacol 48:573-577. (Pubitemid 26254692)
75. Sukbuntherng J, Cropp G, Hannah A, Wagner GS, Shawver LK, Antonian L. 2001. Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. J Pharm Pharmacol 53:1629-1636. (Pubitemid 34044251)
76. Guentert TW, Huang JD, Qie S. 1982. Disposition of quinidine in the rabbit. J Pharm Sci 71:812-815.
77. Iven H. 1977. The Pharmacokinetics and organ distribution of ajmaline and quinidine in the mouse. Naumyn-Schmiedberg's Arch Pharmacol 298:43-50. (Pubitemid 8102025)
78. Ueda CT, Ballard BE, Rowland M. 1977. Concentration- time effects on quinidine disposition kinetics in rhesus monkeys. J Pharmacol Exp Ther 200:459-468. (Pubitemid 8089834)
79. Mroszczak EJ, Lee FW, Combs D, Sarnquist FH, Huang BL, Wu AT, Tokes LG, Maddox ML, Cho DK. 1987. Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. Drug Metab Dispos 15:618-626. (Pubitemid 18004616)
80. Ramanathan-Girish S, McColm J, Clements JM, Taupin P, Barrowcliffe S, Hevizi J, Safrin S, Moore C, Patou G, Moser H, Gadd A, Hoch U, Jiang V, Lofland D, Johnson KW. 2004. Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimicrob Agents Chemother 48:4835-4842. (Pubitemid 39577691)
81. Matsushita H, Suzuki H, Sugiyama Y, Sawada Y, Iga T, Hanano M, Kawaguchi Y. 1990. Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals. J Pharmacobiodyn 13:602-611. (Pubitemid 20386462)
82. Doyle E, Chasseaud LF, Miller JN. 1982. Comparative pharmacokinetics of frusemide in female rhesus monkeys, cynomolgus monkeys and baboons. Comp Biochem Physiol C 71C:89-93. (Pubitemid 12188860)
83. Hirai J, Miyazaki H, Taneike T. 1992. The pharmacokinetics and pharmacodynamics of furosemide in the anaesthetized dog. J Vet Pharmacol Ther 15:231-239.
84. Prandota J, Pruitt AW. 1991. Pharmacokinetic, biliary excretion, and metabolic studies of 14C furosemide in the rat. Xenobiotica 21:725-736.
85. Ritschel WA, Vachharajani NN, Johnson RD, Hussain AS. 1991. Interspecies scaling of the pharmacokinetic parameters of coumarin among six different mammalian species. Meth Find Exp Clin Pharmacol 13:697-702.
86. Lin JH, Chiba M, Balani SK, Chen I-WU, Kwei G, Vastag KJ, Nishime JA. 1996. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 24: 1111-1120. (Pubitemid 26346225)
87. Balani SK, Woolf EJ, Hoagland VL, Sturgill MG, Deutsch PI, Yeh KC, Lin JH. 1996. Disposition of indinavir, a potent HIV-I protease inhibitor, after an oral dose in humans. Drug Metab Dispos 24: 1389-1392. (Pubitemid 26427178)
88. Nakamura S, Kurobe N, Kashimoto S, Ohue T, Takase Y, Shimizu M. 1983. Pharmacokinetics of AT-266 administered orally to mice, rats, dogs and monkeys. Antimicrob Agents Chemother 24:54-60.
89. Somogyi AA, Bochner F. 1988. The absorption and disposition of enoxacin in healthy subjects. J Clin Pharmacol 28:707-713. (Pubitemid 19017355)
90. Nakamura S, Kurobe N, Ohue T, Hashimoto M, Shimizu M. 1990. Pharmacokinetics of a novel quinolone, AT-4140, in animals. Antimicrob Agents Chemother 34:89-93. (Pubitemid 20019969)
91. Montay G, Bruno R, Vergniol JC, Ebmeier M, Le Roux Y, Guimart C, Frydman A, Chassard D, Thebault JJ. 1994. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg. J Clin Pharmacol 34:1071-1076. (Pubitemid 24362585)
92. Howell SR, Hicks DR, Scatina JA, Sisenwine SF. 1994. Pharmacokinetics of venlafaxine and o-desmethylvenlafaxine in laboratory animals. Xenobiotica 24:315-327. (Pubitemid 24169005)
93. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WI, Chiang ST. 1992. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active o-desmethyl metabolite. J Clin Pharmacol 32:716-724.
94. Krieter PA, Gohdes M, Musick TJ, Duncanson FP, Bridson WE. 2008. Pharmacokinetics, disposition, and metabolism of bicifadine in humans. Drug Metab Dispos 36:252-259. (Pubitemid 351185736)
95. Musick TJ, Gohdes M, Duffy A, Erickson DA, Krieter PA. 2008. Pharmacokinetics, disposition, and metabolism of bicifadine in the mouse, rat, and monkey. Drug Metab Dispos 36:241-251. (Pubitemid 351185735)
96. Yeung PKF, Mosher SJ, Quilliam MA, Montague TJ. 1990. Species comparison of pharmacokinetics and metabolism of diltiazem in humans, dogs, rabbits, and rats. Drug Metab Dispos 18:1055-1059.
97. Brazell RK, Pask YH, Woolridge CB, McCue B, Basker R, Couch R, York B. 1990. Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors. Drug Metab Disp 18:435-440. (Pubitemid 20220965)
98. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. 1991. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 8:1351-1359 (rcd4).
99. Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, Matson J, Sasmor H, Cummins L, Levin AA. 2003. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 20-O-(2- methoxyethyl) modified antisense oligonucleotide: Comparison across species. Drug Metab Dispos 31: 1419-1428. (Pubitemid 37310332)
100. Sewell KL, Geary RS, Baker BF, Glover JM, Mant TG, Yu RZ, Tami JA, Dorr FA. 2002. Phase I trial of ISIS 104838, a 20-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 303:1334-1343. (Pubitemid 35424421)
101. Nowak G. 1991. Pharmacokinetics of Hirudin. Semin Thromb Hemost 15:293-330.
102. Oikawa K, Kamimura H, Watanabe T, Miyamoto I, Higuchi S. 2001. Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys. Thromb Res 101:493-500. (Pubitemid 32367926)
103. Oikawa K, Watanabe T, Miyamoto I, Higuchi S. 2000. Determination, pharmacokinetics and protein binding of a novel tissue-type plasminogen activator, pamiteplase in human plasma. Xenobiotica 30:993-1003. (Pubitemid 30944987)
104. Keith JC, Ferranti TJ, Misra B, Frederick T, Rup B, McCarthy K, Faulkner R, Bush L, Schaub RG. 1994. Evaluation of recombinant human factor IX: Pharmacokinetic studies in the rat and the dog. Thromb Haemost 73:101-105.
105. McCarthy K, Stewart P, Sigman J, Read M, Keith JC, Brinkhous KM, Nichols TC, Schaub RG. 2002. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. Thromb Haemost 87:824-830. (Pubitemid 34516609)
106. White G, Shapiro A, Ragni M, Garzone P, Goodfellow J, Tubridy K, Courter S. 1998. Clinical evaluation of recombinant factor IX. Semin Hematol 35:33-38.
107. Martin U, Kohler, Sponer G, Strein K. 1992. Pharmacokinetics of the Novel recombinant plasminogen activator BM 06.022 in rats, dogs, and non-human primates. Fibrinolysis 6:39-43.
108. Martin U, Mollendorff EV, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. 1991. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemost 66:569-574.
109. Kurihara A, Naganuma H, Hisaoka M, Tokiwa H, Kawahara Y. 1992. Prediction of human pharmacokinetics of panipenem-betamipron, a new carbapenem, from animal data. Antimicrob Agents Chemother 36:1810-1816.
110. Efthymiopoulos C, Battaglia R, Strolin Benedetti M. 1991. Animal pharmacokinetics and interspecies scaling of FCE 22101, a penem antibiotic. J Antimicrob Chemother 4:517-526.
111. Jannuzzo MG, Mandelli M, Benedetti MS, Moro E, Carnovali M, Vaiani R, Sassella D. 1989. Pharmacokinetics and tolerance of a new penem antibiotic, FCE 22101, in healthy volunteers after a single intravenous dose. Eur J Clin Pharmacol 36: 633-635. (Pubitemid 19175879)
112. Patel BA, Boudinot FD, Schinazi RF, Gallo JM, Chu CK. 1990. Comparative pharmacokinetics and interspecies scaling of 30-azido-30-deoxythymidine (AZT) in several mammalian species. J Pharmacobiodyn 13:206-211. (Pubitemid 20229054)
113. Cui D, Subramanian R, Shou M, Yu X, Wallace MA, Braun MP, Arison BH, Yergey JA, Prueksaritanont T. 2004. In vitro and in vivo metabolism of a potent and selective integrin alpha(v)beta(3) antagonist in rats, dogs, and monkeys. Drug Metab Dispos 32:848-861.
114. Prueksaritanont T, Fernandez-Metzler C, Meng Y, Barrish A, Halczenko W, Rodan SB, Hutchinson JH, Duggan ME, Lin JH. 2004. Disposition of a novel and potent alpha(v)beta3 antagonist in animals, and extrapolation to man. Xenobiotica 34: 103-115.
115. Pahlman I, Edholm M, Kankaanranta S, Odell M-L. 1998. Pharmacokinetics of susalimod, a highly biliary-excreted sulphasalazine analogue, in various species. Nonpredictable human clearance by allometric scaling. Pharm Pharmacol Commun 4:494-498.
116. Scatina JA, Hicks DR, Kraml M, Cayen MN. 1989. Disposition of a new tetrahydrocarbazole analgesic drug in laboratory animals and man. Xenobiotica 19:991-1002. (Pubitemid 19230093)
117. Kawakami J, Yamamoto K, Sawada Y, Iga T. 1994. Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data. J Pharmacokinet Biopharm 22:207-227. (Pubitemid 24378180)
118. Hayakawa H, Fukushima Y, Kato H, Fukumoto H, Kadota T, Yamamoto H, Kuroiwa H, Nishigaki J, Tsuji A. 2003. Metabolism and disposition of novel desfluoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters. Drug Metab Dispos 31:1409-1418. (Pubitemid 37310331)
119. Gajjar DA, Bello A, Ge Z, Christopher L, Grasela DM. 2003. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother 47:2256-2263. (Pubitemid 36753581)
120. Mcgovern JP, Williams MG, Stewart JC. 1988. Interspecies comparison of acivicin pharmacokinetics. Drug Metab Dispos 16:18.
121. Lave T, Portmann R, Schenker Gianni, Guenz A, Girometta M-A, Schmitt M. 1999. Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor. J Pharm Pharmacol 51:85-91. (Pubitemid 29097274)
122. Feng MR, Loo J, Wright J. 1998. Disposition of the antipsychotic agent CI-I007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling. Drug Metab Disp 26:982-988.